Literature DB >> 9069506

Low dose interferon-alpha is safe in patients with myasthenia gravis.

H Bolay, R Karabudak, K Varli, O Saribas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9069506      PMCID: PMC1064180          DOI: 10.1136/jnnp.62.3.302-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

2.  Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.

Authors:  G Piccolo; D Franciotta; M Versino; E Alfonsi; M Lombardi; G Poma
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

3.  IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis.

Authors:  M Shenoy; S Baron; B Wu; E Goluszko; P Christadoss
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

4.  Myasthenia gravis during interferon alfa therapy.

Authors:  A P Batocchi; A Evoli; S Servidei; M T Palmisani; F Apollo; P Tonali
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.